Fulton Breakefield Broenniman LLC Sells 700 Shares of Pfizer Inc. $PFE

Fulton Breakefield Broenniman LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 6.8% in the second quarter, HoldingsChannel reports. The firm owned 9,639 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. Fulton Breakefield Broenniman LLC’s holdings in Pfizer were worth $234,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Advisory Group Advisory Services LLC boosted its holdings in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 388 shares in the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 395 shares in the last quarter. Trust Co of the South boosted its holdings in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 441 shares in the last quarter. Charter Oak Capital Management LLC boosted its holdings in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 444 shares in the last quarter. Finally, Ballentine Partners LLC boosted its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after buying an additional 458 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Price Performance

Pfizer stock opened at $25.67 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm has a market capitalization of $145.95 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The company has a fifty day simple moving average of $24.79 and a 200-day simple moving average of $24.15. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.